A day ahead of its first-quarter earnings call, Boston Scientific Corp. touted one-year data from the INTREPID study, which evaluated its Vercise direct brain stimulation (DBS) system to treat the symptoms of Parkinson's disease. Among the data highlights was an overall sustained improvement in quality of life. Read More
